Weight loss
262 trials, 99,791 people: how the obesity drugs actually compare
The most complete comparison yet published pooled
262 randomised trials. At one year against lifestyle
changes alone, tirzepatide led on weight (−14.9%), followed by
CagriSema (−14.8%), oral semaglutide (−10.9%) and injectable
semaglutide (−9.8%).
Injectable semaglutide was the only one linked to
lower all-cause mortality (RR 0.81) and
fewer heart attacks (RR 0.72), and both it and
tirzepatide were linked to less heart failure. On body composition,
tirzepatide cut fat mass the most, by 25.7%, and also showed the largest
drop in measured lean mass, by 8.3%.
Why it matters
“Which drug is best” has no single answer — the
largest scale drop and the best cardiovascular signal were not the same
medication. That is a decision to make with a physician who is reading
your labs and your goals, not one to make from a headline.
Read the lean-mass number carefully
Dr. Jim Bowen, our Chief Medical Officer, makes this point often:
DXA and bioimpedance scales like InBody report fat-free mass,
and they do not cleanly separate contractile muscle from the fat stored
inside and between muscle and from shifts in body water. Some of a
measured “lean mass” decline can be intramuscular fat and
fluid leaving — which is a good thing — rather than muscle
you actually need. It is a reason to track the trend with a provider
and keep protein and resistance training in the plan, not a reason to
avoid the medication.
The caveat
The mortality and heart findings come largely from trials in high-risk
cardiovascular patients, so they do not transfer cleanly to a healthier
person taking the same drug for 20 pounds.
Nong K et al. BMJ, 8 July 2026;394:e372161.
Network meta-analysis, 262 RCTs, 99,791 participants, 12–172 weeks.
PubMed 42419792
At Apex MD Every Bloodwork-First tier
includes an InBody body-composition scan, and our GLP-1 programs include
labs and unlimited provider visits — so the trend gets read by
someone who knows what the number does and does not mean.
The GLP-1 program →
Brain health
A structured lifestyle program measurably slowed cognitive decline
Over 1,065 adults aged 60–77 at high risk of
dementia, across 11 countries, were randomised for
two years to either a structured, supervised multidomain
lifestyle program or general health advice.
Both groups improved. But the structured group improved
faster — 0.31 SD a year against 0.20, a
between-group difference of 0.11 SD per year
(95% CI 0.06–0.15, p<0.0001). Adherence in the structured arm ran
71.6%, and fewer people dropped out of it than out of the advice arm.
Why it matters
This is the difference between being told what to do and being taken
through it. The same advice, delivered with structure, supervision and
monitoring, produced measurably better cognitive trajectories over two
years.
The caveat
Both arms improved, and with no untreated control some of that gain is
people getting better at the tests. The trial measured cognitive
scores over two years, not whether anyone went on to develop dementia.
Crivelli L et al. (LatAm-FINGERS). The Lancet,
1 Aug 2026;408(10553):417–429. Single-blind multicentre RCT, 1,065
adults, 2 years.
PubMed 42442374
At Apex MD Structure is the whole
model: a physician-built protocol, coaching and nutrition guidance, and
visits that keep you on it rather than a plan you are left to run alone.
Concierge care →
Exercise
Exercise is now good enough to be called cancer treatment
Pooling 21 randomised trials, structured exercise
programs in people with cancer were associated with
23% lower overall mortality (HR 0.77), 17% better
disease-free survival (HR 0.83) and 26% lower cancer-specific mortality
(RR 0.74). The authors graded the certainty as moderate — high by
the standards of exercise research.
Why it matters
The language has shifted. Exercise during cancer care used to be
justified by quality of life. This puts it in the conversation as
adjuvant therapy, alongside the drugs.
The caveat
The benefit concentrated in people who actually adhered, in aerobic
programs, and in early-stage disease. The trial base leans heavily on
breast cancer.
Tzang CC et al. British Journal of Sports
Medicine, 15 Sept 2026. Meta-analysis of 21 RCTs.
PubMed 42744658
At Apex MD Concierge Elite includes exercise physiology support and coaching alongside the medical plan, because the training is part of the treatment, not a nice-to-have. Concierge care →
Daily movement
How fast you walk matters as much as how far
Among 64,743 UK Biobank participants wearing
accelerometers, the lowest mortality risk was not at the biggest step
count. It was at 7,500–10,000 steps a day walked at around
100 steps per minute (HR 0.57 against the least active group).
For people who barely move, pace did much of the work on its own: under
5,000 steps a day, walking at 80 steps per minute was linked to
28% lower mortality risk than a stroll.
Why it matters
If 10,000 steps feels out of reach, walking your existing steps
faster is the cheaper intervention — and on these numbers, not a
lesser one.
The caveat
Observational. One week of movement was used to predict eight years of
mortality, and people who walk briskly differ from people who
don’t in ways no statistical adjustment fully removes.
Wei L et al. British Journal of Sports
Medicine, 8 Sept 2026. Prospective cohort, 64,743 adults, median 8
years, 1,697 deaths.
PubMed 42711120
At Apex MD Your InBody scan and portal trends show whether the walking is actually changing anything — which is the only way to know it is worth keeping up. How we track progress →
Cardiometabolic
Semaglutide lowered inflammation — and it started before the weight came off
In a prespecified analysis of 17,604 patients followed
for an average of more than three years, semaglutide cut hsCRP — a
standard marker of inflammation — by
37.8% at two years.
The timing is the interesting part. The drop was visible by
weeks four to eight, before major weight loss, and it
appeared even in people who did not lose much weight at all. It was also
independent of LDL cholesterol and of whether the patient was on a
statin.
Why it matters
It suggests these medications are doing something beyond making the
scale move, and that inflammation is worth measuring alongside weight
— early, when it is already changing.
The caveat
An analysis like this can show that two things move together, not that
one causes the other; adjusting for hsCRP only partly explains the
cardiovascular benefit. The trial was funded by the drug’s
manufacturer, and several authors are employees or shareholders.
Plutzky J et al. (SELECT). Circulation,
15 Sept 2026;154(11):976–991. Prespecified secondary analysis of an
RCT, 17,604 patients, mean follow-up 39.8 months.
PubMed 42610271
At Apex MD Inflammatory and metabolic
markers are read at baseline and retested as you go, so you can see the
changes that happen before the scale shows them.
Bloodwork-First →
How we pick these. We favour randomised trials and
large pooled analyses in major journals over press releases and
preprints, we read the paper rather than the coverage, and we tell you
who funded it when it matters. If a finding is preliminary, animal-only
or unpublished, we either say so plainly or leave it out. This month we
left out a widely covered drug result because the company has not
released a single number, and a mouse lifespan study that does not yet
mean anything for people.
Want your own numbers, not the averages?
Every study above is a population. Your labs are you. An Apex MD
provider reads your bloodwork and builds from what it actually says.
Take the 2-minute assessment
The Longevity Briefing is educational and is not
medical advice, a diagnosis, or a recommendation to start or stop any
treatment. Talk to a licensed provider about your own care.
